Latest Earnings
Equities
Stock Analysis
Stock Movers
Deals
Gainers And Losers
IPOs
Technology
Artificial Intelligence
Web Stories
Benzinga Inspire
Can-Fite BioPharma
PRIOR TO PHASE III PSORIASIS DATA RELEASE CAN FITE REPORTS THAT PICLIDENOSON DESTROYS PATHOLOGICAL SKIN CELLS IN VITRO
Piclidenoson has been out-licensed for the indication of psoriasis in certain major markets
Sponsored
Can-Fite to Conduct Investor Meetings during the J.P. Morgan Healthcare Conference
Sponsored
Dawson James - Can-Fite (CANF) Buy Rated - Expected Milestones
Can-Fite in a letter to shareholders outlined the milestones ahead for the year. Click here for the full report COMFORT-Plaque Psoriasis: Topline Phase 3 Psoriasis Data Expected Q122
Sponsored
CAN-FITE ISSUES LETTER TO SHAREHOLDERS
Q1 2022: Psoriasis Phase III Data & Commencement of Enrollment in Phase IIb NASH H1 2022: Commencement of Enrollment in Phase III Liver Cancer
Sponsored
FOLLOWING COMPLETE CLEARANCE OF CANCER LESIONS IN ADVANCED LIVER CANCER PATIENT, CAN-FITE IS FILING PATENT APPLICATIONS FOR THE TREATMENT OF VARIOUS ADVANCED SOLID TUMORS
Namodenoson Headed into Pivotal Phase III Liver Cancer Study
Sponsored
Positive Data from Phase IIa Can-Fite NASH Study Published in Leading Peer Reviewed Scientific Journal
The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.
Sponsored
